Skip to main content
Premium Trial:

Request an Annual Quote

Incyte, SmithKline License Xenometrix's Patented Gene Expression Profiling

Premium

BOULDER, Colo.--Xenometrix, a biotechnology firm here announced last month that it granted licenses to both Incyte and SmithKline Beecham for its gene expression profiling technology. The nonexclusive license for the technology, for which Xenometrix received a US patent in September, covers the collection of gene expression profiles utilizing all methods, including high-density microarrays. Gene Logic, Rosetta Inpharmatics, Cerep, Affymetrix, and Aurora Biosciences are among other companies that have licensed the Xenometrix technology. SmithKline is Xenometrix's first large pharmaceutical customer.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.